Inolimomab
Top View
- 4 Chimeric and Humanized Antibodies Have a Longer Circulating Half-Life and Reduced Immunogenicity [Adair, F 2002]. 1.5 Objectiv
- WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
- Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
- Press Release Leukotac
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- WO 2018/191746 Al 18 October 2018 (18.10.2018) W !P O PCT
- Specialty Pipeline: March 2021
- Antibody-Drug Analogues
- Secondary Treatment of Acute Graft-Versus-Host Disease: a Critical Review
- Long-Term Follow-Up of Corticosteroid Refractory Acute GVHD Treated with an Inolimomab-Based Algorithm: a Single Center Experience
- PDCO Agenda of the 16-19 October 2018 Meeting
- Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens
- The Therapeutic Potential of Anti-CD25 Antibodies
- (12) Patent Application Publication (10) Pub. No.: US 2015/0322155A1 Zhao (43) Pub
- Wo 2012/149405 A2
- Customs Tariff - Schedule Xxi - 1
- Minutes PDCO 16-19 October 2018
- Tim Malawi Mai Multe